Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B

NEW YORK and CLEVELAND, Jan. 19 (Korea Bizwire) — Abeona Therapeutics Inc. (Nasdaq:ABEO), a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/226/16) for Abeona’s gene therapy program ABO-101 for children impacted by [...]